

Commissioning policy

Treatment (brand name, manufacturer if applicable)	Infliximab
For the treatment of	Uveitis
Background	<p>Infliximab is an inhibitor of tumour necrosis factor (TNF). It is given by subcutaneous injection.</p> <p>This treatment is excluded from PbR tariff.</p> <p>It is not licensed for the treatment of uveitis</p>
Commissioning position	<p>NHS Calderdale CCG will not routinely fund the use of Infliximab in the treatment of uveitis</p> <p>No robust evidence of cost-effectiveness available so the CCG is not able to assure itself that this is a cost-effective use of resource</p>
Effective from	March 2011
Summary of evidence/rationale	There is no NICE/SMC guidance
Date	March 2011
Policy to be reviewed by	March 2013
Contact for this policy	Helen Foster – Medicines Management Lead Helen.Foster@calderdaleccg.nhs.uk